Goldman Sachs Health Care Conference

Transcription

1 Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations

2 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory, or clinical results, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen s most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen s most recent Forms 10-K, 10-Q, and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of June 14, 2006 and expressly disclaims any duty to update information contained in this presentation. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company s results may be affected by our ability to successfully market both new and existing products domestically and internationally, sales growth of recently launched products, difficulties or delays in manufacturing our products, and regulatory developments (domestic or foreign) involving current and future products and manufacturing facilities. We depend on third parties for a significant portion of our Enbrel (etanercept) supply and limits on supply may constrain ENBREL sales. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans, and managed care providers, and may be affected by domestic and international trends toward managed care and health care cost containment as well as US legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage, and pricing of our products. Furthermore, our research, testing, pricing, marketing, and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify side effects or manufacturing problems with our products after they are on the market. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated, or circumvented by our competitors. Further, some raw materials, medical devices, and component parts for our products are supplied by sole third-party suppliers. Our business may be impacted by government investigations, litigation, and products liability claims. 2

3 Key Investor Issues for Discussion Our approach to commercialization Growth prospects for key marketed products Initial thoughts on launching key pipeline products Summary of data presentations at ASCO 3

4 Commercialization Based on Evidence-Based Marketing Decision to Market Build a Clinical Evidence Base That Underpins Why It s the Best Choice for Patients Product Strategy Teams Global Development Leader Global Commercial Leader Global Regulatory Leader Global Operations Leader Global Project Manager Managing the product lifecycle 4

5 Applying Evidence-Based Marketing Approach to Aranesp Patient Preference (%) 100% 80% 60% 40% 20% 0% % of CKD Patients Who Would Prefer QM darbepoetin alfa 88% 4% 8% Darbepoetin alfa Epoetin alfa Missing Unknown Medical Affairs study shows patients would prefer darbepoetin alfa QM versus epoetin alfa QW or Q2W in CKD Extended dosing provides significant benefit for patients SureClick launched in EU and filed in the US 5

6 Neulasta : ASCO Guidelines Aligned With Others First- and Subsequent-Cycle CSF Use (Primary Prophylaxis) Neutropenic Guideline Event Risk NCCN 2005 ASCO 2006 EORTC 2006 Moderate to High Use CSF > 20% Use CSF ~ 20% Use CSF 20% Intermediate Consider CSF = 10% 20% Recommend < 20% (with risk factors) Consider CSF = 10 20% US Label Administration of Neulasta beginning in the first cycle of chemotherapy is now approved for patients receiving myelosuppressive chemotherapy associated with at least a 17% risk of FN 6

7 Enbrel : a Focus on Improving Growth Issue Reimbursement Hurdles Higher patient costs Increased prior authorization Our Response Support Services to Improve Access Co-pay support Enbrel Hotline Increased Competitive Activity Expand treatable population 27% of RA addressable patients are treated with a biologic Psoriasis is not treated aggressively 7-year safety data; sustained efficacy over time; soluble receptors vs MABs SureClick expands delivery options (upon approval) Improve awareness through medical education and DTC/DTP promotion 7

8 Building Value Propositions for Key Pipeline Products Panitumumab: a fully human antibody Efficacy in EGFr + and tumors Low immunogenicity and infusion reactions Flexible dosing with no premedication requirement Denosumab: a fully human antibody selective to RANKL Rapid reduction in bone turnover Potential for enhanced compliance AMG 706: a multikinase inhibitor Investigating applicability to broad tumor types Potential for convenient oral therapy 8

9 We Had Significant Data Presentations at ASCO Aranesp : interim phase II data suggest major response in MDS Panitumumab: phase II studies point to anti-tumor activity independent of tumor EGFr expression levels in mcrc AMG 706: phase I dose finding study suggests antitumor activity in thyroid cancer Denosumab: phase II studies point to rapid suppression of bone turnover in advanced cancer patients Apo2L/TRAIL: phase I study shows no dose limiting toxicities with administration 9

10 Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations